Miller D L
Department of Diagnostic Radiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
Radiology. 1989 Sep;172(3 Pt 2):1007-11. doi: 10.1148/172.3.1007.
All members and fellows of the Society of Cardiovascular and Interventional Radiology were surveyed to determine current patterns of heparin use in angiography. Five hundred responses (68%) were received. In general, significant differences exist across the United States in the mean heparin dose for angiography, mean dose for angioplasty, heparin concentration in flush solutions, and, especially, frequency with which heparin is mixed with nonionic contrast media. Few respondents routinely use systemic (bolus) heparinization for angiography. Heparin concentration in flush solutions varies from 0 IU/L to 12,000 IU/L. Eleven percent of respondents mix heparin with nonionic contrast agents, at a median dose of 5 IU/mL. Results of this survey reveal patterns of practice but do not represent a standard of practice. Protocols for heparin use should be based on experimental evidence, and heparin dosage must be individualized for each procedure and each patient. Large-scale, prospective studies of the merits of systemic heparinization and of mixing heparin with nonionic contrast agents are needed.
心血管与介入放射学会的所有成员及会员均接受了调查,以确定血管造影术中肝素的当前使用模式。共收到500份回复(68%)。总体而言,美国各地在血管造影术的平均肝素剂量、血管成形术的平均剂量、冲洗液中的肝素浓度,尤其是肝素与非离子型造影剂混合的频率方面存在显著差异。很少有受访者常规使用全身(推注)肝素化进行血管造影。冲洗液中的肝素浓度从0 IU/L到12,000 IU/L不等。11%的受访者将肝素与非离子型造影剂混合,中位剂量为5 IU/mL。本次调查结果揭示了实践模式,但并不代表实践标准。肝素使用方案应基于实验证据,并且肝素剂量必须针对每个程序和每个患者进行个体化调整。需要对全身肝素化以及肝素与非离子型造影剂混合的优点进行大规模前瞻性研究。